Surgerii

Surgerii (术锐机器人) has emerged as a leading developer of single-port surgical robots in China, distinguished by its proprietary snake-arm instrument technology. Founded by Professor Xu Kai of Shanghai Jiao Tong University, the company became the first in China to receive NMPA approval for a single-port laparoscopic surgical robot and has since expanded into European markets with CE certification.

Company Overview

Professor Xu Kai established Surgerii in 2014 after nearly two decades of research in surgical robotics. His academic background includes doctoral training at Columbia University under Professor Russell Taylor, widely regarded as a pioneer in medical robotics. This foundation led to the development of the “deformable dural continuum mechanism,” a core technology that enables Surgerii’s snake-like surgical instruments to operate with flexibility impossible for rigid-arm systems.

The company entered China’s innovative medical device fast-track approval pathway in 2020, becoming the first single-port surgical robot to achieve this milestone. By June 2023, Surgerii secured NMPA marketing approval, and in August 2025, the company obtained CE certification under MDR EU2017/745 for the European market.

Corporate headquarters are located in Beijing, with government support from the Ministry of Industry and Information Technology, Ministry of Science and Technology, and various municipal science commissions. The company signed an IPO guidance agreement with CITIC Securities in March 2023, initiating the A-share listing process.

Core Products

SHURUI Single-Port Surgical Robot (SR-ENS-600)

The SHURUI system represents Surgerii’s flagship product, utilizing snake-like instruments made from superelastic nickel-titanium alloy. Unlike conventional multi-arm surgical robots that require multiple incisions, SHURUI delivers a 3D endoscope and three surgical instruments through a single 2.5cm multi-channel trocar, enabling precise operations through one skin incision.

The system has received NMPA approval for urology, gynecology, general surgery, and thoracic surgery. Its CE certification covers the same specialties for both adult and pediatric patients, making it the only CE-certified single-port surgical robot approved for pediatric use and the first Chinese surgical robot certified for patients of all age groups.

Technology and Innovation

Surgerii’s competitive advantage centers on the “deformable dural continuum mechanism,” which differs fundamentally from the rigid wire-driven mechanical arms used in traditional surgical robots. The snake-arm design provides superior flexibility and payload capacity while eliminating the “chopstick effect” that limits conventional single-port surgical approaches.

Key technical features include:

• Multi-degree-of-freedom movement through continuum kinematics
• High payload capacity despite flexible structure
• Redundant structural backbone design ensuring continued operation even with single backbone fracture
• Dual independent hardware systems for safety monitoring
• Motion scaling for enhanced precision during delicate procedures

The company has filed over 805 patents and applications globally as of April 2025, establishing broad intellectual property protection. An independent patent landscape analysis confirmed that Surgerii’s technology achieves disruptive innovation distinguished from existing surgical robotics patents.

Market Presence

Within China, Surgerii has established clinical cooperation with over 70 Grade A tertiary hospitals. The company has performed more than 3,000 surgeries domestically and participated in nearly 50 procedures internationally. Clinical applications span multiple specialties, with surgical techniques developed by Surgerii filling gaps in clinical practice across Asia.

Notable clinical achievements include Asia’s first pure single-port radical prostatectomy and partial nephrectomy, as well as the world’s first retroperitoneal adrenal tumor resection via single-port approach. Surgerii has also demonstrated pediatric applications, performing procedures on patients as young as 7 days old.

For international expansion, the company established the European Clinical Excellence Center in 2025 through collaboration with IRCAD, a leading institution for minimally invasive surgical training. Strategic focus has shifted toward high-end European markets following CE certification.

Key Milestones

• 2014: Company founded by Professor Xu Kai
• 2019: Series A funding led by Shunwei Capital
• 2020: First single-port surgical robot in China to enter innovative medical device fast-track pathway
• 2021: Strategic cooperation agreement with Medtronic; first clinical surgery completed
• 2023 (March): Signed IPO guidance agreement with CITIC Securities
• 2023 (June): NMPA approval for urology and gynecology
• 2024 (February): NMPA approval expanded to additional indications
• 2025 (May): NMPA approval extended to general surgery and thoracic surgery
• 2025 (August): CE certification obtained for European market
• 2025 (December): Series D funding of $100 million closed

Frequently Asked Questions

What surgeries can the SHURUI robot perform?

The SHURUI system is approved for urologic laparoscopic procedures, gynecologic laparoscopic procedures, general laparoscopic procedures, and thoracoscopic procedures. Specific applications include radical prostatectomy, partial nephrectomy, adrenal tumor resection, cholecystectomy, and various gynecologic surgeries.

Is Surgerii publicly traded?

Surgerii is not yet publicly traded. The company initiated its A-share IPO process in March 2023 by signing a guidance agreement with CITIC Securities, but has not completed the listing as of January 2026.

How does SHURUI compare to da Vinci SP?

Both systems are single-port surgical robots, but SHURUI uses snake-arm instruments based on continuum mechanism technology rather than the cable-driven articulated instruments in da Vinci SP. Surgerii claims its approach offers advantages in flexibility and pediatric applications. Notably, SHURUI has CE certification for pediatric use, while da Vinci SP is indicated only for adult patients in Europe.

Who are Surgerii’s major investors?

Key investors include Shunwei Capital (Lei Jun’s fund), Medtronic, Shanghai Biomedical Fund, SDIC Capital, Tianfeng Capital, Zhengxingu Capital, V Star Capital, and Loyal Valley Capital. Shunwei Capital has been the largest institutional investor, participating from Series A through Series C rounds.